Related Experiment Video
Updated: Aug 12, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Substituted imidazoles as glucagon receptor antagonists
L L Chang1, K L Sidler, M A Cascieri
1Department of Medicinal Chemical Research, Merck Research Laboratories, Rahway, NJ 07065, USA. linda_chang@merck.com
Bioorganic & Medicinal Chemistry Letters
|September 11, 2001
Summary
Researchers optimized a triarylimidazole compound to improve binding affinity with the human glucagon receptor. Key structural modifications enhanced glucagon receptor binding and selectivity over p38MAP kinase.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Triarylimidazole compounds were explored as potential modulators of the human glucagon receptor.
- Initial lead compounds exhibited modest activity and lacked selectivity.
Purpose of the Study:
- To optimize a triarylimidazole lead compound for enhanced binding affinity to the human glucagon receptor.
- To achieve significant selectivity over p38MAP kinase.
Main Methods:
- Structure-activity relationship (SAR) studies were conducted on the triarylimidazole scaffold.
- Chemical modifications focused on substituents at the imidazole C4-aryl group.
Main Results:
- Identification of 2- and/or 4-alkyl or alkyloxy substituents on the imidazole C4-aryl group as critical for activity.
- Achieved significant enhancement in binding affinity (e.g., compound 41, IC(50)=0.053 microM).
- Demonstrated high selectivity (>1000x) for the glucagon receptor over p38MAP kinase.
Conclusions:
- Specific alkyl or alkyloxy substitutions on the imidazole C4-aryl group are key determinants for potent and selective glucagon receptor modulation.
- This optimization strategy yielded promising drug candidates for targeting the glucagon receptor.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...